Pharma BD Deal Intelligence

Novo Nordisk A/S / Biosplice Therapeutics, Inc.

2024 · Licensing/Option · Complete

Novo Nordisk and Biosplice Therapeutics entered a preclinical collaboration around Biosplice's selective DYRK inhibitors, which have shown beta-cell proliferation in animal models and human islet cells. Novo Nordisk funds further preclinical development and holds an exclusive option to license Biosplice intellectual property focused on cardiometabolic disorders; financial terms (upfront, milestones, royalties) were not disclosed.

Key facts

• Announced Jun 13, 2024
• Deal type Licensing/Option

Related deals

• Novo Nordisk A/S / Emisphere Technologies (2020)
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. (2019)
• Novo Nordisk A/S / Vivtex Inc. (2026)
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. (2021)
• Novo Nordisk A/S / Forma Therapeutics Holdings Inc. (2022)
• Novo Nordisk A/S / Inversago Pharma (2023)

← Browse all deals  ·  How we score deals

More: 2024 deals  ·  Novo Nordisk A/S deals